|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:MRPL49-ARL2 (FusionGDB2 ID:54759) |
Fusion Gene Summary for MRPL49-ARL2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: MRPL49-ARL2 | Fusion gene ID: 54759 | Hgene | Tgene | Gene symbol | MRPL49 | ARL2 | Gene ID | 740 | 402 |
| Gene name | mitochondrial ribosomal protein L49 | ADP ribosylation factor like GTPase 2 | |
| Synonyms | C11orf4|L49mt|MRP-L49|NOF|NOF1 | ARFL2 | |
| Cytomap | 11q13.1 | 11q13.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | 39S ribosomal protein L49, mitochondrialmitochondrial large ribosomal subunit protein mL49neighbor of FAUnext to FAU | ADP-ribosylation factor-like protein 2ADP-ribosylation factor-like 2 | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | Q13405 | Q9Y2Y0 | |
| Ensembl transtripts involved in fusion gene | ENST00000524482, ENST00000534078, ENST00000526171, ENST00000279242, ENST00000531705, | ENST00000246747, ENST00000529384, ENST00000533729, | |
| Fusion gene scores | * DoF score | 4 X 4 X 2=32 | 1 X 1 X 1=1 |
| # samples | 4 | 1 | |
| ** MAII score | log2(4/32*10)=0.321928094887362 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(1/1*10)=3.32192809488736 | |
| Context | PubMed: MRPL49 [Title/Abstract] AND ARL2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | MRPL49(64889896)-ARL2(64787891), # samples:2 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | ARL2 | GO:0031116 | positive regulation of microtubule polymerization | 10831612|20740604 |
| Tgene | ARL2 | GO:0034260 | negative regulation of GTPase activity | 10831612 |
| Tgene | ARL2 | GO:0051457 | maintenance of protein location in nucleus | 18234692 |
| Fusion gene breakpoints across MRPL49 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across ARL2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | LUAD | TCGA-49-AARQ-01A | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + |
| ChimerDB4 | LUAD | TCGA-49-AARQ-01A | MRPL49 | chr11 | 64889896 | - | ARL2 | chr11 | 64787891 | + |
Top |
Fusion Gene ORF analysis for MRPL49-ARL2 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-3CDS | ENST00000524482 | ENST00000246747 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + |
| intron-3CDS | ENST00000524482 | ENST00000529384 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + |
| intron-intron | ENST00000524482 | ENST00000533729 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + |
| In-frame | ENST00000534078 | ENST00000246747 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + |
| In-frame | ENST00000534078 | ENST00000529384 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + |
| 5CDS-intron | ENST00000534078 | ENST00000533729 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + |
| In-frame | ENST00000526171 | ENST00000246747 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + |
| In-frame | ENST00000526171 | ENST00000529384 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + |
| 5CDS-intron | ENST00000526171 | ENST00000533729 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + |
| In-frame | ENST00000279242 | ENST00000246747 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + |
| In-frame | ENST00000279242 | ENST00000529384 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + |
| 5CDS-intron | ENST00000279242 | ENST00000533729 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + |
| In-frame | ENST00000531705 | ENST00000246747 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + |
| In-frame | ENST00000531705 | ENST00000529384 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + |
| 5CDS-intron | ENST00000531705 | ENST00000533729 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000534078 | MRPL49 | chr11 | 64889896 | + | ENST00000246747 | ARL2 | chr11 | 64787891 | + | 659 | 114 | 326 | 658 | 111 |
| ENST00000534078 | MRPL49 | chr11 | 64889896 | + | ENST00000529384 | ARL2 | chr11 | 64787891 | + | 577 | 114 | 36 | 329 | 97 |
| ENST00000526171 | MRPL49 | chr11 | 64889896 | + | ENST00000246747 | ARL2 | chr11 | 64787891 | + | 649 | 104 | 316 | 648 | 111 |
| ENST00000526171 | MRPL49 | chr11 | 64889896 | + | ENST00000529384 | ARL2 | chr11 | 64787891 | + | 567 | 104 | 26 | 319 | 97 |
| ENST00000279242 | MRPL49 | chr11 | 64889896 | + | ENST00000246747 | ARL2 | chr11 | 64787891 | + | 642 | 97 | 309 | 641 | 111 |
| ENST00000279242 | MRPL49 | chr11 | 64889896 | + | ENST00000529384 | ARL2 | chr11 | 64787891 | + | 560 | 97 | 19 | 312 | 97 |
| ENST00000531705 | MRPL49 | chr11 | 64889896 | + | ENST00000246747 | ARL2 | chr11 | 64787891 | + | 634 | 89 | 301 | 633 | 111 |
| ENST00000531705 | MRPL49 | chr11 | 64889896 | + | ENST00000529384 | ARL2 | chr11 | 64787891 | + | 552 | 89 | 11 | 304 | 97 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000534078 | ENST00000246747 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + | 0.22548431 | 0.7745157 |
| ENST00000534078 | ENST00000529384 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + | 0.10774393 | 0.8922561 |
| ENST00000526171 | ENST00000246747 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + | 0.19530278 | 0.8046972 |
| ENST00000526171 | ENST00000529384 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + | 0.12797137 | 0.8720286 |
| ENST00000279242 | ENST00000246747 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + | 0.21636482 | 0.7836352 |
| ENST00000279242 | ENST00000529384 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + | 0.15981057 | 0.84018946 |
| ENST00000531705 | ENST00000246747 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + | 0.21834981 | 0.7816502 |
| ENST00000531705 | ENST00000529384 | MRPL49 | chr11 | 64889896 | + | ARL2 | chr11 | 64787891 | + | 0.1503198 | 0.8496802 |
Top |
Fusion Genomic Features for MRPL49-ARL2 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for MRPL49-ARL2 |
| Go to FGviewer for the breakpoints of chr11:64889896-chr11:64787891 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| MRPL49 | ARL2 |
| FUNCTION: Together with ARL2, plays a role in the nuclear translocation, retention and transcriptional activity of STAT3. May play a role as an effector of ARL2. {ECO:0000269|PubMed:18234692}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | ARL2 | chr11:64889896 | chr11:64787891 | ENST00000246747 | 2 | 5 | 125_128 | 113.0 | 185.0 | Nucleotide binding | GTP | |
| Tgene | ARL2 | chr11:64889896 | chr11:64787891 | ENST00000529384 | 2 | 6 | 125_128 | 113.0 | 225.33333333333334 | Nucleotide binding | GTP | |
| Tgene | ARL2 | chr11:64889896 | chr11:64787891 | ENST00000533729 | 0 | 4 | 125_128 | 0 | 158.0 | Nucleotide binding | GTP | |
| Tgene | ARL2 | chr11:64889896 | chr11:64787891 | ENST00000533729 | 0 | 4 | 23_30 | 0 | 158.0 | Nucleotide binding | GTP | |
| Tgene | ARL2 | chr11:64889896 | chr11:64787891 | ENST00000533729 | 0 | 4 | 66_70 | 0 | 158.0 | Nucleotide binding | GTP |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | ARL2 | chr11:64889896 | chr11:64787891 | ENST00000246747 | 2 | 5 | 23_30 | 113.0 | 185.0 | Nucleotide binding | GTP | |
| Tgene | ARL2 | chr11:64889896 | chr11:64787891 | ENST00000246747 | 2 | 5 | 66_70 | 113.0 | 185.0 | Nucleotide binding | GTP | |
| Tgene | ARL2 | chr11:64889896 | chr11:64787891 | ENST00000529384 | 2 | 6 | 23_30 | 113.0 | 225.33333333333334 | Nucleotide binding | GTP | |
| Tgene | ARL2 | chr11:64889896 | chr11:64787891 | ENST00000529384 | 2 | 6 | 66_70 | 113.0 | 225.33333333333334 | Nucleotide binding | GTP |
Top |
Fusion Gene Sequence for MRPL49-ARL2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >In-frame_ENST00000534078_ENST00000246747_TCGA-49-AARQ-01A_MRPL49_chr11_64889896_+_ARL2_chr11_64787891_length(transcript)=659nt_BP=114nt AGTTGCGCGCACAGAAGGCTGGCGTAGCAGGTAAAGATGGCAGCTACCATGTTCCGGGCTACGCTGCGGGGATGGAGAACCGGTGTCCAG CGGGGCTGCGGGCTACGGCTGTTGCGCCTGGCCGGAGCAACCCTCCTCATCTTTGCTAATAAGCAGGACCTGCCTGGAGCACTGTCCTCT AACGCCATCCGCGAGGTCCTGGAGCTGGACTCCATCCGCAGCCACCACTGGTGCATCCAGGGCTGCAGCGCCGTCACCGGGGAGAACCTG CTGCCGGGCATCGACTGGCTCCTGGATGACATTTCCAGCCGCATTTTCACAGCTGACTGAACCACTCCAGATGCCCCCCACCTAGCAGTC CAGGTCCCTCAACCTTCACCAAACACTACCCATGGGGGGTTGGGAGTCAGCCGGCCAAACTAACACTCCCCCTCCTCCACCCCAGCCTGC TGCTGCTACTGCTGCCCGCTGCTGCTCTGTGGCCACCCGGCTCCCATGGCGGGAGGGCTGTGCCCTGGCTGTCTCTCTGGCTCCTGACCT GGCCTTTGGCTACCATACCAAGAAGAGAGGGCTGGGCGGGGAGGAGCTGCTACTGCTGCTACCGAGGCTGTGGGCCTCATCCTTCACTCA >In-frame_ENST00000534078_ENST00000246747_TCGA-49-AARQ-01A_MRPL49_chr11_64889896_+_ARL2_chr11_64787891_length(amino acids)=111AA_start in transcript=326_stop in transcript=658 MNHSRCPPPSSPGPSTFTKHYPWGVGSQPAKLTLPLLHPSLLLLLLPAAALWPPGSHGGRAVPWLSLWLLTWPLATIPRREGWAGRSCYC -------------------------------------------------------------- >In-frame_ENST00000534078_ENST00000529384_TCGA-49-AARQ-01A_MRPL49_chr11_64889896_+_ARL2_chr11_64787891_length(transcript)=577nt_BP=114nt AGTTGCGCGCACAGAAGGCTGGCGTAGCAGGTAAAGATGGCAGCTACCATGTTCCGGGCTACGCTGCGGGGATGGAGAACCGGTGTCCAG CGGGGCTGCGGGCTACGGCTGTTGCGCCTGGCCGGAGCAACCCTCCTCATCTTTGCTAATAAGCAGGACCTGCCTGGAGCACTGTCCTCT AACGCCATCCGCGAGGTCCTGGAGCTGGACTCCATCCGCAGCCACCACTGGTGCATCCAGGGCTGCAGCGCCGTCACCGGGGAGAACCTG CTGCCGGGCATCGACTGGCTCCTGGATGACATTTCCAGCCGCATTTTCACAGCTGACTGAACCACTCCAGATGCCCCCCACCTAGCAGTC CAGCCTGCTGCTGCTACTGCTGCCCGCTGCTGCTCTGTGGCCACCCGGCTCCCATGGCGGGAGGGCTGTGCCCTGGCTGTCTCTCTGGCT CCTGACCTGGCCTTTGGCTACCATACCAAGAAGAGAGGGCTGGGCGGGGAGGAGCTGCTACTGCTGCTACCGAGGCTGTGGGCCTCATCC >In-frame_ENST00000534078_ENST00000529384_TCGA-49-AARQ-01A_MRPL49_chr11_64889896_+_ARL2_chr11_64787891_length(amino acids)=97AA_start in transcript=36_stop in transcript=329 MAATMFRATLRGWRTGVQRGCGLRLLRLAGATLLIFANKQDLPGALSSNAIREVLELDSIRSHHWCIQGCSAVTGENLLPGIDWLLDDIS -------------------------------------------------------------- >In-frame_ENST00000526171_ENST00000246747_TCGA-49-AARQ-01A_MRPL49_chr11_64889896_+_ARL2_chr11_64787891_length(transcript)=649nt_BP=104nt ACAGAAGGCTGGCGTAGCAGGTAAAGATGGCAGCTACCATGTTCCGGGCTACGCTGCGGGGATGGAGAACCGGTGTCCAGCGGGGCTGCG GGCTACGGCTGTTGCGCCTGGCCGGAGCAACCCTCCTCATCTTTGCTAATAAGCAGGACCTGCCTGGAGCACTGTCCTCTAACGCCATCC GCGAGGTCCTGGAGCTGGACTCCATCCGCAGCCACCACTGGTGCATCCAGGGCTGCAGCGCCGTCACCGGGGAGAACCTGCTGCCGGGCA TCGACTGGCTCCTGGATGACATTTCCAGCCGCATTTTCACAGCTGACTGAACCACTCCAGATGCCCCCCACCTAGCAGTCCAGGTCCCTC AACCTTCACCAAACACTACCCATGGGGGGTTGGGAGTCAGCCGGCCAAACTAACACTCCCCCTCCTCCACCCCAGCCTGCTGCTGCTACT GCTGCCCGCTGCTGCTCTGTGGCCACCCGGCTCCCATGGCGGGAGGGCTGTGCCCTGGCTGTCTCTCTGGCTCCTGACCTGGCCTTTGGC TACCATACCAAGAAGAGAGGGCTGGGCGGGGAGGAGCTGCTACTGCTGCTACCGAGGCTGTGGGCCTCATCCTTCACTCAGTTGTGAAAT >In-frame_ENST00000526171_ENST00000246747_TCGA-49-AARQ-01A_MRPL49_chr11_64889896_+_ARL2_chr11_64787891_length(amino acids)=111AA_start in transcript=316_stop in transcript=648 MNHSRCPPPSSPGPSTFTKHYPWGVGSQPAKLTLPLLHPSLLLLLLPAAALWPPGSHGGRAVPWLSLWLLTWPLATIPRREGWAGRSCYC -------------------------------------------------------------- >In-frame_ENST00000526171_ENST00000529384_TCGA-49-AARQ-01A_MRPL49_chr11_64889896_+_ARL2_chr11_64787891_length(transcript)=567nt_BP=104nt ACAGAAGGCTGGCGTAGCAGGTAAAGATGGCAGCTACCATGTTCCGGGCTACGCTGCGGGGATGGAGAACCGGTGTCCAGCGGGGCTGCG GGCTACGGCTGTTGCGCCTGGCCGGAGCAACCCTCCTCATCTTTGCTAATAAGCAGGACCTGCCTGGAGCACTGTCCTCTAACGCCATCC GCGAGGTCCTGGAGCTGGACTCCATCCGCAGCCACCACTGGTGCATCCAGGGCTGCAGCGCCGTCACCGGGGAGAACCTGCTGCCGGGCA TCGACTGGCTCCTGGATGACATTTCCAGCCGCATTTTCACAGCTGACTGAACCACTCCAGATGCCCCCCACCTAGCAGTCCAGCCTGCTG CTGCTACTGCTGCCCGCTGCTGCTCTGTGGCCACCCGGCTCCCATGGCGGGAGGGCTGTGCCCTGGCTGTCTCTCTGGCTCCTGACCTGG CCTTTGGCTACCATACCAAGAAGAGAGGGCTGGGCGGGGAGGAGCTGCTACTGCTGCTACCGAGGCTGTGGGCCTCATCCTTCACTCAGT >In-frame_ENST00000526171_ENST00000529384_TCGA-49-AARQ-01A_MRPL49_chr11_64889896_+_ARL2_chr11_64787891_length(amino acids)=97AA_start in transcript=26_stop in transcript=319 MAATMFRATLRGWRTGVQRGCGLRLLRLAGATLLIFANKQDLPGALSSNAIREVLELDSIRSHHWCIQGCSAVTGENLLPGIDWLLDDIS -------------------------------------------------------------- >In-frame_ENST00000279242_ENST00000246747_TCGA-49-AARQ-01A_MRPL49_chr11_64889896_+_ARL2_chr11_64787891_length(transcript)=642nt_BP=97nt GCTGGCGTAGCAGGTAAAGATGGCAGCTACCATGTTCCGGGCTACGCTGCGGGGATGGAGAACCGGTGTCCAGCGGGGCTGCGGGCTACG GCTGTTGCGCCTGGCCGGAGCAACCCTCCTCATCTTTGCTAATAAGCAGGACCTGCCTGGAGCACTGTCCTCTAACGCCATCCGCGAGGT CCTGGAGCTGGACTCCATCCGCAGCCACCACTGGTGCATCCAGGGCTGCAGCGCCGTCACCGGGGAGAACCTGCTGCCGGGCATCGACTG GCTCCTGGATGACATTTCCAGCCGCATTTTCACAGCTGACTGAACCACTCCAGATGCCCCCCACCTAGCAGTCCAGGTCCCTCAACCTTC ACCAAACACTACCCATGGGGGGTTGGGAGTCAGCCGGCCAAACTAACACTCCCCCTCCTCCACCCCAGCCTGCTGCTGCTACTGCTGCCC GCTGCTGCTCTGTGGCCACCCGGCTCCCATGGCGGGAGGGCTGTGCCCTGGCTGTCTCTCTGGCTCCTGACCTGGCCTTTGGCTACCATA CCAAGAAGAGAGGGCTGGGCGGGGAGGAGCTGCTACTGCTGCTACCGAGGCTGTGGGCCTCATCCTTCACTCAGTTGTGAAATAAACCGC >In-frame_ENST00000279242_ENST00000246747_TCGA-49-AARQ-01A_MRPL49_chr11_64889896_+_ARL2_chr11_64787891_length(amino acids)=111AA_start in transcript=309_stop in transcript=641 MNHSRCPPPSSPGPSTFTKHYPWGVGSQPAKLTLPLLHPSLLLLLLPAAALWPPGSHGGRAVPWLSLWLLTWPLATIPRREGWAGRSCYC -------------------------------------------------------------- >In-frame_ENST00000279242_ENST00000529384_TCGA-49-AARQ-01A_MRPL49_chr11_64889896_+_ARL2_chr11_64787891_length(transcript)=560nt_BP=97nt GCTGGCGTAGCAGGTAAAGATGGCAGCTACCATGTTCCGGGCTACGCTGCGGGGATGGAGAACCGGTGTCCAGCGGGGCTGCGGGCTACG GCTGTTGCGCCTGGCCGGAGCAACCCTCCTCATCTTTGCTAATAAGCAGGACCTGCCTGGAGCACTGTCCTCTAACGCCATCCGCGAGGT CCTGGAGCTGGACTCCATCCGCAGCCACCACTGGTGCATCCAGGGCTGCAGCGCCGTCACCGGGGAGAACCTGCTGCCGGGCATCGACTG GCTCCTGGATGACATTTCCAGCCGCATTTTCACAGCTGACTGAACCACTCCAGATGCCCCCCACCTAGCAGTCCAGCCTGCTGCTGCTAC TGCTGCCCGCTGCTGCTCTGTGGCCACCCGGCTCCCATGGCGGGAGGGCTGTGCCCTGGCTGTCTCTCTGGCTCCTGACCTGGCCTTTGG CTACCATACCAAGAAGAGAGGGCTGGGCGGGGAGGAGCTGCTACTGCTGCTACCGAGGCTGTGGGCCTCATCCTTCACTCAGTTGTGAAA >In-frame_ENST00000279242_ENST00000529384_TCGA-49-AARQ-01A_MRPL49_chr11_64889896_+_ARL2_chr11_64787891_length(amino acids)=97AA_start in transcript=19_stop in transcript=312 MAATMFRATLRGWRTGVQRGCGLRLLRLAGATLLIFANKQDLPGALSSNAIREVLELDSIRSHHWCIQGCSAVTGENLLPGIDWLLDDIS -------------------------------------------------------------- >In-frame_ENST00000531705_ENST00000246747_TCGA-49-AARQ-01A_MRPL49_chr11_64889896_+_ARL2_chr11_64787891_length(transcript)=634nt_BP=89nt AGCAGGTAAAGATGGCAGCTACCATGTTCCGGGCTACGCTGCGGGGATGGAGAACCGGTGTCCAGCGGGGCTGCGGGCTACGGCTGTTGC GCCTGGCCGGAGCAACCCTCCTCATCTTTGCTAATAAGCAGGACCTGCCTGGAGCACTGTCCTCTAACGCCATCCGCGAGGTCCTGGAGC TGGACTCCATCCGCAGCCACCACTGGTGCATCCAGGGCTGCAGCGCCGTCACCGGGGAGAACCTGCTGCCGGGCATCGACTGGCTCCTGG ATGACATTTCCAGCCGCATTTTCACAGCTGACTGAACCACTCCAGATGCCCCCCACCTAGCAGTCCAGGTCCCTCAACCTTCACCAAACA CTACCCATGGGGGGTTGGGAGTCAGCCGGCCAAACTAACACTCCCCCTCCTCCACCCCAGCCTGCTGCTGCTACTGCTGCCCGCTGCTGC TCTGTGGCCACCCGGCTCCCATGGCGGGAGGGCTGTGCCCTGGCTGTCTCTCTGGCTCCTGACCTGGCCTTTGGCTACCATACCAAGAAG AGAGGGCTGGGCGGGGAGGAGCTGCTACTGCTGCTACCGAGGCTGTGGGCCTCATCCTTCACTCAGTTGTGAAATAAACCGCTCCTTGCC >In-frame_ENST00000531705_ENST00000246747_TCGA-49-AARQ-01A_MRPL49_chr11_64889896_+_ARL2_chr11_64787891_length(amino acids)=111AA_start in transcript=301_stop in transcript=633 MNHSRCPPPSSPGPSTFTKHYPWGVGSQPAKLTLPLLHPSLLLLLLPAAALWPPGSHGGRAVPWLSLWLLTWPLATIPRREGWAGRSCYC -------------------------------------------------------------- >In-frame_ENST00000531705_ENST00000529384_TCGA-49-AARQ-01A_MRPL49_chr11_64889896_+_ARL2_chr11_64787891_length(transcript)=552nt_BP=89nt AGCAGGTAAAGATGGCAGCTACCATGTTCCGGGCTACGCTGCGGGGATGGAGAACCGGTGTCCAGCGGGGCTGCGGGCTACGGCTGTTGC GCCTGGCCGGAGCAACCCTCCTCATCTTTGCTAATAAGCAGGACCTGCCTGGAGCACTGTCCTCTAACGCCATCCGCGAGGTCCTGGAGC TGGACTCCATCCGCAGCCACCACTGGTGCATCCAGGGCTGCAGCGCCGTCACCGGGGAGAACCTGCTGCCGGGCATCGACTGGCTCCTGG ATGACATTTCCAGCCGCATTTTCACAGCTGACTGAACCACTCCAGATGCCCCCCACCTAGCAGTCCAGCCTGCTGCTGCTACTGCTGCCC GCTGCTGCTCTGTGGCCACCCGGCTCCCATGGCGGGAGGGCTGTGCCCTGGCTGTCTCTCTGGCTCCTGACCTGGCCTTTGGCTACCATA CCAAGAAGAGAGGGCTGGGCGGGGAGGAGCTGCTACTGCTGCTACCGAGGCTGTGGGCCTCATCCTTCACTCAGTTGTGAAATAAACCGC >In-frame_ENST00000531705_ENST00000529384_TCGA-49-AARQ-01A_MRPL49_chr11_64889896_+_ARL2_chr11_64787891_length(amino acids)=97AA_start in transcript=11_stop in transcript=304 MAATMFRATLRGWRTGVQRGCGLRLLRLAGATLLIFANKQDLPGALSSNAIREVLELDSIRSHHWCIQGCSAVTGENLLPGIDWLLDDIS -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for MRPL49-ARL2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for MRPL49-ARL2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for MRPL49-ARL2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | MRPL49 | C0025202 | melanoma | 1 | CTD_human |
| Tgene | ARL2 | C0025202 | melanoma | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies